• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Nanobody stabilization of G protein-coupled receptor conformational states.纳米抗体稳定 G 蛋白偶联受体构象状态。
Curr Opin Struct Biol. 2011 Aug;21(4):567-72. doi: 10.1016/j.sbi.2011.06.011. Epub 2011 Jul 21.
2
Antibody fragments for stabilization and crystallization of G protein-coupled receptors and their signaling complexes.用于稳定G蛋白偶联受体及其信号复合物并使其结晶的抗体片段。
Methods Enzymol. 2015;557:247-58. doi: 10.1016/bs.mie.2015.01.010. Epub 2015 Mar 24.
3
Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation.变构纳米抗体揭示了G蛋白偶联受体激活的动态范围和多种机制。
Nature. 2016 Jul 21;535(7612):448-52. doi: 10.1038/nature18636. Epub 2016 Jul 13.
4
Nanobodies to Study G Protein-Coupled Receptor Structure and Function.用于研究G蛋白偶联受体结构与功能的纳米抗体
Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:19-37. doi: 10.1146/annurev-pharmtox-010716-104710. Epub 2016 Dec 7.
5
Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs.纳米抗体:用于成像、稳定和调节 G 蛋白偶联受体的新途径。
Mol Cell Endocrinol. 2019 Mar 15;484:15-24. doi: 10.1016/j.mce.2019.01.021. Epub 2019 Jan 26.
6
The Impact of Nanobodies on G Protein-Coupled Receptor Structural Biology and Their Potential as Therapeutic Agents.纳米抗体对 G 蛋白偶联受体结构生物学的影响及其作为治疗剂的潜力。
Mol Pharmacol. 2024 Sep 17;106(4):155-163. doi: 10.1124/molpharm.124.000974.
7
Unlocking the secrets of the gatekeeper: methods for stabilizing and crystallizing GPCRs.揭开“守门人”的秘密:稳定和结晶G蛋白偶联受体的方法。
Biochim Biophys Acta. 2013 Nov;1828(11):2583-91. doi: 10.1016/j.bbamem.2013.07.013. Epub 2013 Jul 18.
8
NMR analysis of GPCR conformational landscapes and dynamics.NMR 分析 GPCR 构象景观和动态。
Mol Cell Endocrinol. 2019 Mar 15;484:69-77. doi: 10.1016/j.mce.2018.12.019. Epub 2019 Jan 25.
9
GPCR Activation States Induced by Nanobodies and Mini-G Proteins Compared by NMR Spectroscopy.通过 NMR 光谱比较纳米抗体和微蛋白诱导的 GPCR 激活态。
Molecules. 2020 Dec 17;25(24):5984. doi: 10.3390/molecules25245984.
10
Identifying multiple active conformations in the G protein-coupled receptor activation landscape using computational methods.使用计算方法在G蛋白偶联受体激活态势中识别多个活性构象
Methods Cell Biol. 2017;142:173-186. doi: 10.1016/bs.mcb.2017.07.009. Epub 2017 Sep 11.

引用本文的文献

1
Developing nanobodies as allosteric molecular chaperones of glucocerebrosidase function.开发纳米抗体作为葡萄糖脑苷脂酶功能的变构分子伴侣。
Nat Commun. 2025 May 27;16(1):4890. doi: 10.1038/s41467-025-60134-4.
2
Growth inhibition of Saccharomyces cerevisiae by SUMO-specific nanobodies.SUMO特异性纳米抗体对酿酒酵母的生长抑制作用
Sci Rep. 2025 May 26;15(1):18368. doi: 10.1038/s41598-025-02380-6.
3
A nanobody that binds to the backside of the ubiquitin conjugating enzyme Ube2G2 differentially affects interactions with its partner E3 Ligases.一种与泛素结合酶Ube2G2背面结合的纳米抗体对其与伴侣E3连接酶的相互作用有不同影响。
Commun Biol. 2025 Apr 16;8(1):614. doi: 10.1038/s42003-025-08038-3.
4
Intersection of GPCR trafficking and cAMP signaling at endomembranes.G蛋白偶联受体(GPCR)在内膜上的运输与环磷酸腺苷(cAMP)信号传导的交汇
J Cell Biol. 2025 Apr 7;224(4). doi: 10.1083/jcb.202409027. Epub 2025 Mar 25.
5
Principles and Design of Molecular Tools for Sensing and Perturbing Cell Surface Receptor Activity.用于感知和扰动细胞表面受体活性的分子工具的原理与设计
Chem Rev. 2025 Mar 12;125(5):2665-2702. doi: 10.1021/acs.chemrev.4c00582. Epub 2025 Feb 25.
6
Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years.纳米抗体的发现:过去五年中它们的应用和潜力的全面综述。
J Nanobiotechnology. 2024 Oct 26;22(1):661. doi: 10.1186/s12951-024-02900-y.
7
Structural basis of paramyxo- and pneumovirus polymerase inhibition by non-nucleoside small-molecule antivirals.副黏病毒和肺病毒聚合酶非核苷小分子抗病毒药物抑制的结构基础。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0080024. doi: 10.1128/aac.00800-24. Epub 2024 Aug 20.
8
Challenges of Protein-Protein Docking of the Membrane Proteins.膜蛋白的蛋白质-蛋白质对接挑战。
Methods Mol Biol. 2024;2780:203-255. doi: 10.1007/978-1-0716-3985-6_12.
9
Nanobody engineering: computational modelling and design for biomedical and therapeutic applications.纳米抗体工程:用于生物医学和治疗应用的计算建模与设计
FEBS Open Bio. 2025 Feb;15(2):236-253. doi: 10.1002/2211-5463.13850. Epub 2024 Jun 19.
10
Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons.纳米抗体在抗感染中的应用:利用自然界的微小武器。
World J Microbiol Biotechnol. 2024 May 21;40(7):209. doi: 10.1007/s11274-024-03990-4.

本文引用的文献

1
Structure of the human histamine H1 receptor complex with doxepin.人源组胺 H1 受体复合物与多塞平的结构。
Nature. 2011 Jun 22;475(7354):65-70. doi: 10.1038/nature10236.
2
Structure of an agonist-bound human A2A adenosine receptor.激动剂结合的人 A2A 腺苷受体结构。
Science. 2011 Apr 15;332(6027):322-7. doi: 10.1126/science.1202793. Epub 2011 Mar 10.
3
Crystal structure of metarhodopsin II.视紫红质 II 的晶体结构。
Nature. 2011 Mar 31;471(7340):651-5. doi: 10.1038/nature09789. Epub 2011 Mar 9.
4
The structural basis of agonist-induced activation in constitutively active rhodopsin.激动剂诱导的固有激活状态视紫红质激活的结构基础。
Nature. 2011 Mar 31;471(7340):656-60. doi: 10.1038/nature09795. Epub 2011 Mar 9.
5
The structural basis for agonist and partial agonist action on a β(1)-adrenergic receptor.激动剂和部分激动剂在β(1)-肾上腺素能受体上作用的结构基础。
Nature. 2011 Jan 13;469(7329):241-4. doi: 10.1038/nature09746.
6
Structure and function of an irreversible agonist-β(2) adrenoceptor complex.不可逆激动剂-β(2)肾上腺素能受体复合物的结构与功能。
Nature. 2011 Jan 13;469(7329):236-40. doi: 10.1038/nature09665.
7
Structure of a nanobody-stabilized active state of the β(2) adrenoceptor.β2 肾上腺素能受体的纳米体稳定的活性状态结构。
Nature. 2011 Jan 13;469(7329):175-80. doi: 10.1038/nature09648.
8
Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic beta2-microglobulin variant.β2-微球蛋白变异体构象二聚体的纳米体捕获结构域的原子结构。
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1314-9. doi: 10.1073/pnas.1008560108. Epub 2011 Jan 10.
9
Therapeutic potential of β-arrestin- and G protein-biased agonists.β-arrestin 和 G 蛋白偏向激动剂的治疗潜力。
Trends Mol Med. 2011 Mar;17(3):126-39. doi: 10.1016/j.molmed.2010.11.004. Epub 2010 Dec 21.
10
Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist.人源多巴胺 D3 受体与 D2/D3 选择性拮抗剂复合物的结构。
Science. 2010 Nov 19;330(6007):1091-5. doi: 10.1126/science.1197410.

纳米抗体稳定 G 蛋白偶联受体构象状态。

Nanobody stabilization of G protein-coupled receptor conformational states.

机构信息

Department of Molecular and Cellular Interactions, Vlaams Instituut voor Biotechnologie & Structural Biology Brussels, Vrije Universiteit Brussel, Pleinlaan 2, B-1050 Brussels, Belgium.

出版信息

Curr Opin Struct Biol. 2011 Aug;21(4):567-72. doi: 10.1016/j.sbi.2011.06.011. Epub 2011 Jul 21.

DOI:10.1016/j.sbi.2011.06.011
PMID:21782416
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3166880/
Abstract

Remarkable progress has been made in the field of G protein-coupled receptor (GPCR) structural biology during the past four years. Several obstacles to generating diffraction quality crystals of GPCRs have been overcome by combining innovative methods ranging from protein engineering to lipid-based screens and microdiffraction technology. The initial GPCR structures represent energetically stable inactive-state conformations. However, GPCRs signal through different G protein isoforms or G protein-independent effectors upon ligand binding suggesting the existence of multiple ligand-specific active states. These active-state conformations are unstable in the absence of specific cytosolic signaling partners representing new challenges for structural biology. Camelid single chain antibody fragments (nanobodies) show promise for stabilizing active GPCR conformations and as chaperones for crystallogenesis.

摘要

在过去的四年中,G 蛋白偶联受体(GPCR)结构生物学领域取得了显著进展。通过结合从蛋白质工程到基于脂质的筛选和微衍射技术等创新方法,克服了生成 GPCR 衍射质量晶体的几个障碍。最初的 GPCR 结构代表了能量稳定的无活性状态构象。然而,GPCR 通过配体结合后通过不同的 G 蛋白同工型或 G 蛋白独立效应器信号转导,这表明存在多种配体特异性的活性状态。这些活性状态构象在没有特定的细胞溶质信号伴侣的情况下是不稳定的,这代表了结构生物学的新挑战。骆驼科单链抗体片段(纳米抗体)有望稳定活性 GPCR 构象,并作为结晶的伴侣。